What are the asthma phenotypes and the corresponding GINA-recommended treatment strategies for each phenotype?

Asthma Phenotypes and GINA Treatment Strategies

GINA recognizes asthma as a heterogeneous disease with multiple phenotypes, and treatment should be targeted based on phenotypic characteristics, particularly Type 2 (T2) inflammation status, rather than using a one-size-fits-all approach. 1, 2

Key Asthma Phenotypes

Type 2 (T2)-High Eosinophilic Asthma

• Characterized by: Elevated blood eosinophils (≥150-300 cells/μL), elevated FeNO (≥19.5-25 ppb), sputum eosinophilia, and allergen sensitization 1, 3
• Clinical features: Better response to inhaled corticosteroids (ICS), often associated with allergic triggers, and may present at any severity level 1, 4
• Treatment response: These patients show excellent response to ICS-based therapy and are candidates for biologic therapies (anti-IgE, anti-IL-5/5R, anti-IL-4R) when severe 1, 3

Type 2-Low (Non-Eosinophilic) Asthma

• Characterized by: Normal or low eosinophil counts, neutrophilic or paucigranulocytic sputum patterns 1, 4
• Clinical features: Often associated with obesity, smoking, late-onset disease, and poorer response to standard ICS therapy 4
• Treatment challenges: Less responsive to corticosteroids, may benefit from macrolide therapy or addressing comorbidities 3

Allergic Asthma Phenotype

• Characterized by: Clear allergen sensitization with positive skin tests or specific IgE, symptoms triggered by allergen exposure 1
• Treatment approach: ICS remains first-line, but omalizumab (anti-IgE) is recommended for severe cases requiring Step 5-6 care in patients ≥12 years 1
• Additional therapy: Subcutaneous immunotherapy conditionally recommended for Steps 2-4 when clear allergen relationship exists 5

Exercise-Induced Bronchoconstriction Phenotype

• Characterized by: Symptoms primarily or exclusively triggered by physical activity 5
• Treatment approach: Pre-exercise ICS-formoterol or SABA, with consideration for daily low-dose ICS if symptoms occur frequently 2

Severe Asthma Phenotypes

Multiple overlapping severe phenotypes exist 3:

• Early-onset allergic severe asthma: High eosinophils, multiple allergen sensitizations
• Late-onset eosinophilic asthma: Adult-onset, persistent eosinophilia despite high-dose ICS
• Corticosteroid-dependent asthma: Requires oral corticosteroids to maintain control
• Severe asthma with fixed airflow limitation: Airway remodeling with irreversible obstruction 1

GINA-Recommended Treatment by Phenotype

For T2-High/Eosinophilic Phenotypes

Mild Asthma (Steps 1-2):

• Preferred Track 1: As-needed low-dose ICS-formoterol (budesonide-formoterol 200/6 μg) 5, 2
• Alternative Track 2: Daily low-dose ICS plus as-needed SABA, or as-needed ICS taken whenever SABA is taken 6, 5
• Critical point: SABA-only treatment is no longer recommended due to increased exacerbation risk 2

Moderate Asthma (Steps 3-4):

• Preferred: Daily low-to-medium dose ICS-formoterol as maintenance PLUS as-needed ICS-formoterol (MART regimen) 5, 2
• Alternative: Medium-dose ICS-LABA with as-needed SABA 6, 5
• Step 4 additions: Consider adding tiotropium (LAMA) for adolescents and adults with inadequate control 5, 3

Severe Asthma (Steps 5-6):

• Foundation: High-dose ICS-LABA with MART approach 5, 2
• Add-on therapies based on biomarkers:
  • Blood eosinophils ≥150 cells/μL: Anti-IL-5 (mepolizumab, reslizumab) or anti-IL-5Rα (benralizumab) 3
  • Blood eosinophils ≥260 cells/μL AND FeNO ≥19.5 ppb: Anti-IgE (omalizumab) shows greatest response 3
  • Blood eosinophils ≥150 cells/μL OR corticosteroid-dependent: Anti-IL-4Rα (dupilumab) regardless of eosinophil level 3
• Additional options: Tiotropium, chronic macrolide therapy (azithromycin), or oral corticosteroids as last resort 5, 3

For T2-Low/Non-Eosinophilic Phenotypes

Treatment approach differs significantly:

• Step 2-4: Standard ICS-LABA therapy, though response may be suboptimal 4
• Step 5: Consider chronic macrolide therapy (azithromycin 250-500 mg three times weekly) irrespective of phenotype 3
• Critical: Address treatable traits including obesity, smoking cessation, GERD, rhinosinusitis 6
• Avoid: Biologic therapies targeting T2 pathways show minimal benefit in this phenotype 3

For Allergic Phenotype (Regardless of Severity)

Specific considerations:

• Steps 2-4: Subcutaneous immunotherapy as adjunct when asthma is controlled and clear allergen relationship exists 5
• Severe allergic asthma: Omalizumab for patients ≥12 years with elevated IgE (30-700 IU/mL) and allergen sensitization 1
• Biomarker guidance: FeNO ≥19.5 ppb and eosinophils ≥260 cells/μL predict best omalizumab response 3

Critical Implementation Points

Assessment before phenotype-directed treatment:

• Confirm diagnosis with spirometry showing reversibility (FEV1 increase ≥12% and ≥200 mL post-bronchodilator) 1
• Measure blood eosinophils, FeNO, and total IgE before initiating biologic therapy 3
• Document allergen sensitization via skin testing or specific IgE 1

Common pitfalls to avoid:

• Never use LABA monotherapy without ICS due to increased mortality risk 7, 8
• Do not assume symptom control equals low exacerbation risk, particularly in severe asthma 6
• Avoid doubling ICS dose during exacerbations in adherent patients—this strategy is ineffective 9
• Do not initiate subcutaneous immunotherapy in severe uncontrolled asthma due to anaphylaxis risk 1, 5

Monitoring strategy:

• Reassess control every 2-6 weeks when stepping up therapy 5
• Use validated tools: Asthma Control Test, Asthma Control Questionnaire 10
• Monitor FEV1 or PEF: ≥80% predicted indicates good control, <60% indicates very poor control 10
• Consider stepping down after ≥3 months of good control 1, 5

Specialist referral indications:

• Step 4 or higher therapy required 10, 5
• Consideration of biologic therapy 1
• Suspected severe asthma or treatment-resistant disease 11
• Phenotypic assessment needed for targeted therapy 6